Benign prostatic hyperplasia

Summary

Benign prostatic hyperplasia (MONDO:0010811) is a disease with 32 cohort genes (149 GWAS associations across 37 studies) and 549 clinical trials. Top therapeutic interventions include tamsulosin, alfuzosin, and solifenacin.

At a glance

• Cohort genes: 32
• GWAS associations: 149
• Clinical trials: 549

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign prostatic hyperplasia
Mondo ID	MONDO:0010811
EFO	EFO:0000284
MeSH	D011470
OMIM	600082
DOID	DOID:11132
ICD-10-CM	N40
NCIT	C2897
SNOMED CT	266569009
UMLS	C1704272
MedGen	312369
Anatomy (UBERON)	UBERON:0002367
Is cancer (heuristic)	no

Also known as: benign hyperplasia of prostate · benign hyperplasia of the prostate · benign prostate hyperplasia · benign prostatic hyperplasia · benign prostatic hyperplasia (disease) · benign prostatic hyperplasia - BPH · benign prostatic Hypertrophy · benign prostatic hypertrophy · BPH · prostate hypertrophy · prostatic hyperplasia, benign · prostatic hypertrophy

Data availability: 149 GWAS associations (37 studies) · 1 HPO phenotype · 11 cell lines.

Disease family

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › prostate disorder › benign prostatic hyperplasia

Related subtypes (4): prostatic cyst, prostate calculus, prostatitis, prostate neoplasm

Genetics & variants

GWAS landscape

149 GWAS associations across 37 studies. Top hits map to 9 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr10:123047691	6e-49		T	0.08
chr5:1344458	1e-47		G	0.07
chr10:123044831	2e-44		T	0.1
rs10886902	1e-43	LINC01153 - RN7SKP167	T	0.09
rs2447853	5e-42	CLPTM1L	A	0.06
rs10886894	8e-39	LINC01153 - RN7SKP167	T	0.1
chr5:1322087	2e-38		C	0.08
rs11084596	4e-38	LINC03103 - RNA5SP471	T	0.07
rs414965	1e-32	CLPTM1L	G	0.08
rs2556378	1e-28	BCL11A	T	0.07
rs381949	2e-28	CLPTM1L	G	1.14
rs971563	3e-28	BCL11A	T	0.1
rs2556376	2e-26	BCL11A	C	0.09
rs7124615	1e-24	BET1L	T	0.13
rs492715	3e-24	SIRT3	G	0.11
rs148678804	1e-22	DNAJC1 - ADIPOR1P1	A	1.34
rs2853677	2e-22	TERT	G	1.12
rs465498	4e-22	CLPTM1L	A	0.08
rs11199879	4e-20	LINC01153 - RN7SKP167	C	1.13
chr10:123045212	8e-20		T	0.09
chr10:22312049	5e-19		G	0.07
chr5:134604215	2e-18		A	0.08
rs9958656	3e-18	GATA6 - CTAGE1	T	1.11
chr8:23460123	3e-18		A	0.06
rs200476	4e-17	RSL24D1P1 - H4C10P	A	1.14
rs7898914	9e-17	DNAJC1 - ADIPOR1P1	A	0.07
rs4548546	2e-16	WDR11	T	1.11
chr6:135288716	2e-16		C	0.05
chr18:19911690	3e-16		G	0.04
chr13:51492374	8e-16		C	0.07

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90476153	Verma A	2024	138,928	243,435	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475261	Verma A	2024	63,608	229,593	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475262	Verma A	2024	34,268	258,933	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478611	Verma A	2024	30,813	64,576	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480406	Verma A	2024	30,813	64,576	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST007507	Gudmundsson J	2018	20,621	280,541	Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
GCST007512	Gudmundsson J	2018	18,138	277,213	Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
GCST90080617	Backman JD	2021	15,936	156,384	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084603	Backman JD	2021	15,936	156,384	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90652192	Liu TY	2025	15,878	84,916	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	50

MAF distribution

Bucket	Variants
common (>=0.05)	48
low_freq (0.01-0.05)	2
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
unknown	20
intergenic_variant	15
intron_variant	15

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr10:123047691				0.228			6e-49	Tier 4: intronic/intergenic
chr5:1344458				0.428			1e-47	Tier 4: intronic/intergenic
chr10:123044831				0.229			2e-44	Tier 4: intronic/intergenic
rs10886902	10	121289750	T>A,C,G	0.198	intergenic_variant	LINC01153 - RN7SKP167	1e-43	Tier 4: intronic/intergenic
rs2447853	5	1332962	A>C,G,T	0.443	intron_variant	CLPTM1L	5e-42	Tier 4: intronic/intergenic
rs10886894	10	121287359	T>C	0.207	intergenic_variant	LINC01153 - RN7SKP167	8e-39	Tier 4: intronic/intergenic
chr5:1322087				0.44			2e-38	Tier 4: intronic/intergenic
rs11084596	19	31614073	T>C	0.388	intergenic_variant	LINC03103 - RNA5SP471	4e-38	Tier 4: intronic/intergenic
rs414965	5	1324006	G>A	0.407	intron_variant	CLPTM1L	1e-32	Tier 4: intronic/intergenic
rs2556378	2	60535367	T>A,C,G	0.161	intron_variant	BCL11A	1e-28	Tier 4: intronic/intergenic
rs381949	5	1322353	G>A	0.415	intron_variant	CLPTM1L	2e-28	Tier 4: intronic/intergenic
rs971563	2	60547638	T>A,C	0.18	intron_variant	BCL11A	3e-28	Tier 4: intronic/intergenic
rs2556376	2	60532897	C>A,G,T	0.193	intron_variant	BCL11A	2e-26	Tier 4: intronic/intergenic
rs7124615	11	186604	T>A,C	0.16	intergenic_variant	BET1L	1e-24	Tier 4: intronic/intergenic
rs492715	11	232491	G>T	0.066	intron_variant	SIRT3	3e-24	Tier 4: intronic/intergenic
rs148678804	10	22138360	G>A,T	0.035	intergenic_variant	DNAJC1 - ADIPOR1P1	1e-22	Tier 4: intronic/intergenic
rs2853677	5	1287079	G>A,C,T	0.421	intron_variant	TERT	2e-22	Tier 4: intronic/intergenic
rs465498	5	1325688	A>C,G,T	0.435	intron_variant	CLPTM1L	4e-22	Tier 4: intronic/intergenic
rs11199879	10	121285698	T>A,C	0.252	intergenic_variant	LINC01153 - RN7SKP167	4e-20	Tier 4: intronic/intergenic
chr10:123045212				0.23			8e-20	Tier 4: intronic/intergenic
chr10:22312049				0.262			5e-19	Tier 4: intronic/intergenic
chr5:134604215				0.123			2e-18	Tier 4: intronic/intergenic
rs9958656	18	22324181	T>A,C	0.43	intron_variant	GATA6 - CTAGE1	3e-18	Tier 4: intronic/intergenic
chr8:23460123				0.414			3e-18	Tier 4: intronic/intergenic
rs200476	6	27800570	A>T	0.162	intergenic_variant	RSL24D1P1 - H4C10P	4e-17	Tier 4: intronic/intergenic
rs7898914	10	22038392	A>G	0.23	intergenic_variant	DNAJC1 - ADIPOR1P1	9e-17	Tier 4: intronic/intergenic
rs4548546	10	120870067	C>G,T	0.31	intron_variant	WDR11	2e-16	Tier 4: intronic/intergenic
chr6:135288716				0.363			2e-16	Tier 4: intronic/intergenic
chr18:19911690				0.445			3e-16	Tier 4: intronic/intergenic
chr13:51492374				0.073			8e-16	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 58 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TBX3	Orphanet:3138	Ulnar-mammary syndrome
TBX5	Orphanet:101016	Romano-Ward syndrome
TBX5	Orphanet:392	Holt-Oram syndrome
HNF1B	Orphanet:1309	Medullary sponge kidney
HNF1B	Orphanet:1331	Familial prostate cancer
HNF1B	Orphanet:2578	Mayer-Rokitansky-Küster-Hauser syndrome type 2
HNF1B	Orphanet:261265	17q12 microdeletion syndrome
HNF1B	Orphanet:93111	HNF1B-related autosomal dominant tubulointerstitial kidney disease
HNF1B	Orphanet:93172	Renal dysplasia, unilateral
HNF1B	Orphanet:93173	Renal dysplasia, bilateral
HNF1B	Orphanet:97363	Unilateral multicystic dysplastic kidney
HNF1B	Orphanet:97364	Bilateral multicystic dysplastic kidney
TERT	Orphanet:146	Differentiated thyroid carcinoma
TERT	Orphanet:1501	Adrenocortical carcinoma
TERT	Orphanet:1775	Dyskeratosis congenita
TERT	Orphanet:2032	Idiopathic pulmonary fibrosis
TERT	Orphanet:2495	Meningioma
TERT	Orphanet:3322	Hoyeraal-Hreidarsson syndrome
TERT	Orphanet:457246	Clear cell sarcoma of kidney
TERT	Orphanet:618	Familial melanoma
TERT	Orphanet:88	Idiopathic aplastic anemia
BCL11A	Orphanet:251380	Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome
BCL11A	Orphanet:619233	Hereditary persistence of fetal hemoglobin-intellectual disability syndrome
PHIP	Orphanet:589905	PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome
GATA5	Orphanet:3303	Tetralogy of Fallot
GATA5	Orphanet:334	Hereditary atrial fibrillation
GATA5	Orphanet:402075	Familial bicuspid aortic valve
UNC13A	Orphanet:803	Amyotrophic lateral sclerosis
RNASEH2B	Orphanet:51	Aicardi-Goutières syndrome
RNASEH2B	Orphanet:689234	RNASEH2B-related hereditary spastic paraplegia
DCC	Orphanet:238722	Familial congenital mirror movements
DCC	Orphanet:2744	Horizontal gaze palsy with progressive scoliosis
DCC	Orphanet:478	Kallmann syndrome
FGFR2	Orphanet:1540	Jackson-Weiss syndrome
FGFR2	Orphanet:1555	Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome
FGFR2	Orphanet:168624	Familial scaphocephaly syndrome, McGillivray type
FGFR2	Orphanet:207	Crouzon syndrome
FGFR2	Orphanet:2363	Lacrimoauriculodentodigital syndrome
FGFR2	Orphanet:313855	FGFR2-related bent bone dysplasia
FGFR2	Orphanet:596008	Antley-Bixler syndrome without genital anomaly or disorder of steroidogenesis
FGFR2	Orphanet:794	Saethre-Chotzen syndrome
FGFR2	Orphanet:87	Apert syndrome
FGFR2	Orphanet:93258	Pfeiffer syndrome type 1
FGFR2	Orphanet:93259	Pfeiffer syndrome type 2
FGFR2	Orphanet:93260	Pfeiffer syndrome type 3
GATA3	Orphanet:2237	Hypoparathyroidism-sensorineural deafness-renal disease syndrome
GATA3	Orphanet:585936	B-lymphoblastic leukemia/lymphoma with hyperdiploidy
GATA6	Orphanet:2140	Congenital diaphragmatic hernia
GATA6	Orphanet:2255	Pancreatic hypoplasia-diabetes-congenital heart disease syndrome
GATA6	Orphanet:3303	Tetralogy of Fallot

Cohort genes → proteins

32 cohort genes, 29 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	32

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SYN3	HGNC:11496	ENSG00000185666	O14994	Synapsin-3	gwas
TBX3	HGNC:11602	ENSG00000135111	O15119	T-box transcription factor TBX3	gwas
TBX5	HGNC:11604	ENSG00000089225	Q99593	T-box transcription factor TBX5	gwas
HNF1B	HGNC:11630	ENSG00000275410	P35680	Hepatocyte nuclear factor 1-beta	gwas
TERT	HGNC:11730	ENSG00000164362	O14746	Telomerase reverse transcriptase	gwas
UGCG	HGNC:12524	ENSG00000148154	Q16739	Ceramide glucosyltransferase	gwas
BCL11A	HGNC:13221	ENSG00000119866	Q9H165	BCL11 transcription factor A	gwas
DLEU1	HGNC:13747	ENSG00000176124	O43261	Leukemia-associated protein 1	gwas
PHIP	HGNC:15673	ENSG00000146247	Q8WWQ0	PH-interacting protein	gwas
GATA5	HGNC:15802	ENSG00000130700	Q9BWX5	Transcription factor GATA-5	gwas
ELOVL6	HGNC:15829	ENSG00000170522	Q9H5J4	Very long chain fatty acid elongase 6	gwas
BTBD3	HGNC:15854	ENSG00000132640	Q9Y2F9	BTB/POZ domain-containing protein 3	gwas
SPTLC3	HGNC:16253	ENSG00000172296	Q9NUV7	Serine palmitoyltransferase 3	gwas
SORCS1	HGNC:16697	ENSG00000108018	Q8WY21	VPS10 domain-containing receptor SorCS1	gwas
STARD4	HGNC:18058	ENSG00000164211	Q96DR4	StAR-related lipid transfer protein 4	gwas
CIMAP1A	HGNC:19905	ENSG00000177947	Q96PU9	Ciliary microtubule associated protein 1A	gwas
DNAJC1	HGNC:20090	ENSG00000136770	Q96KC8	DnaJ homolog subfamily C member 1	gwas
UNC13A	HGNC:23150	ENSG00000130477	Q9UPW8	Protein unc-13 homolog A	gwas
CLPTM1L	HGNC:24308	ENSG00000049656	Q96KA5	Lipid scramblase CLPTM1L	gwas
CTAGE1	HGNC:24346	ENSG00000212710	Q96RT6	cTAGE family member 2	gwas
RNASEH2B	HGNC:25671	ENSG00000136104	Q5TBB1	Ribonuclease H2 subunit B	gwas
DCC	HGNC:2701	ENSG00000187323	P43146	Netrin receptor DCC	gwas
FGFR2	HGNC:3689	ENSG00000066468	P21802	Fibroblast growth factor receptor 2	gwas
MIR3134	HGNC:38254	ENSG00000264354		microRNA 3134	gwas
EBLN1	HGNC:39430	ENSG00000223601	P0CF75	Endogenous Bornavirus-like nucleoprotein 1	gwas
GATA3	HGNC:4172	ENSG00000107485	P23771	Trans-acting T-cell-specific transcription factor GATA-3	gwas
GATA6	HGNC:4174	ENSG00000141448	Q92908	Transcription factor GATA-6	gwas
GCLC	HGNC:4311	ENSG00000001084	P48506	Glutamate–cysteine ligase catalytic subunit	gwas
MACROH2A1	HGNC:4740	ENSG00000113648	O75367	Core histone macro-H2A.1	gwas
H2BC13	HGNC:4748	ENSG00000185130	Q99880	Histone H2B type 1-L	gwas
LINC03103	HGNC:48330	ENSG00000267465		long intergenic non-protein coding RNA 3103	gwas
PITX1-AS1	HGNC:48332	ENSG00000224186		PITX1 antisense RNA 1	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SYN3	Synapsin-3	May be involved in the regulation of neurotransmitter release and synaptogenesis.
TBX3	T-box transcription factor TBX3	Transcriptional repressor involved in developmental processes.
TBX5	T-box transcription factor TBX5	DNA-binding protein that regulates the transcription of several genes and is involved in heart development and limb pattern formation.
HNF1B	Hepatocyte nuclear factor 1-beta	Transcription factor that binds to the inverted palindrome 5’-GTTAATNATTAAC-3'.
TERT	Telomerase reverse transcriptase	Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes.
UGCG	Ceramide glucosyltransferase	Participates in the initial step of the glucosylceramide-based glycosphingolipid/GSL synthetic pathway at the cytosolic surface of the Golgi.
BCL11A	BCL11 transcription factor A	Transcription factor.
DLEU1	Leukemia-associated protein 1	May act as a tumor suppressor.
PHIP	PH-interacting protein	Probable regulator of the insulin and insulin-like growth factor signaling pathways.
GATA5	Transcription factor GATA-5	Transcription factor required during cardiovascular development.
ELOVL6	Very long chain fatty acid elongase 6	Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle.
BTBD3	BTB/POZ domain-containing protein 3	Acts as a key regulator of dendritic field orientation during development of sensory cortex.
SPTLC3	Serine palmitoyltransferase 3	Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-…
STARD4	StAR-related lipid transfer protein 4	Involved in the intracellular transport of cholesterol.
CIMAP1A	Ciliary microtubule associated protein 1A	Outer dense fibers are filamentous structures located on the outside of the axoneme in the midpiece and principal piece of the mammalian sperm tail.
DNAJC1	DnaJ homolog subfamily C member 1	May modulate protein synthesis.
UNC13A	Protein unc-13 homolog A	Plays a role in vesicle maturation during exocytosis as a target of the diacylglycerol second messenger pathway.
CLPTM1L	Lipid scramblase CLPTM1L	Scramblase that mediates the translocation of glucosaminylphosphatidylinositol (alpha-D-GlcN-(1-6)-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol, GlcN-PI) across the endoplasmic reticulum (ER) membrane, from the cytosolic leaflet to th…
RNASEH2B	Ribonuclease H2 subunit B	Non catalytic subunit of RNase H2, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids.
DCC	Netrin receptor DCC	Receptor for netrin required for axon guidance.
FGFR2	Fibroblast growth factor receptor 2	Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic de…
EBLN1	Endogenous Bornavirus-like nucleoprotein 1	May act as an RNA-binding protein.
GATA3	Trans-acting T-cell-specific transcription factor GATA-3	Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes.
GATA6	Transcription factor GATA-6	Transcriptional activator.
GCLC	Glutamate–cysteine ligase catalytic subunit	Catalyzes the ATP-dependent ligation of L-glutamate and L-cysteine and participates in the first and rate-limiting step in glutathione biosynthesis.
MACROH2A1	Core histone macro-H2A.1	Variant histone H2A which replaces conventional H2A in a subset of nucleosomes where it represses transcription.
H2BC13	Histone H2B type 1-L	Core component of nucleosome.

Protein-family classification

Druggable: 8 · Difficult: 9 · Unknown: 15 · Druggable fraction: 0.25

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	8	2.1×	0.200
Enzyme (other)	5	1.9×	0.371
Antibody/Immunoglobulin	2	1.8×	0.600
Kinase	1	0.9×	0.884
Other/Unknown	15	0.8×	0.884
Scaffold/PPI	1	0.5×	0.884

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SYN3	Other/Unknown	no		Synapsin, ATP_grasp_subdomain_1, PreATP-grasp_dom_sf
TBX3	Transcription factor	no		TF_T-box, p53-like_TF_DNA-bd_sf, TF_T-box_CS
TBX5	Transcription factor	no		TF_T-box, p53-like_TF_DNA-bd_sf, TF_T-box_CS
HNF1B	Transcription factor	no		HD, HNF1b_C, HNF-1_N
TERT	Other/Unknown	no		RT_dom, Telomerase_RT, Telomerase_RBD
UGCG	Enzyme (other)	yes	2.4.1.80	Ceramide_glucosylTrfase, Nucleotide-diphossugar_trans
BCL11A	Transcription factor	no		Znf_C2H2_type, Znf_C2H2_sf, Dev/Hematopoietic_TF
DLEU1	Other/Unknown	no
PHIP	Scaffold/PPI	no		Bromodomain, WD40_rpt, WD40/YVTN_repeat-like_dom_sf
GATA5	Transcription factor	no		Znf_GATA, GATA_N, Znf_NHR/GATA
ELOVL6	Enzyme (other)	yes	2.3.1.16	ELO_fam, ELO_CS, ELOVL6
BTBD3	Other/Unknown	no		BTB/POZ_dom, SKP1/BTB/POZ_sf, BACK
SPTLC3	Enzyme (other)	yes	2.3.1.50	Aminotrans_II_pyridoxalP_BS, Aminotransferase_I/II_large, PyrdxlP-dep_Trfase_major
SORCS1	Antibody/Immunoglobulin	yes		PKD_dom, VPS10, Ig-like_fold
STARD4	Other/Unknown	no		START_lipid-bd_dom, START-like_dom_sf, StarD4
CIMAP1A	Other/Unknown	no		SHIPPO-rpt, CIMAP
DNAJC1	Transcription factor	no		SANT/Myb, DnaJ_domain, Homeodomain-like_sf
UNC13A	Other/Unknown	no		C2_dom, PKC_DAG/PE, MUN_dom
CLPTM1L	Other/Unknown	no		CLPTM1
CTAGE1	Other/Unknown	no		cTAGE_MIA/OTOR
RNASEH2B	Enzyme (other)	yes	3.1.26.4	RNase_H2_suB_wHTH, RNase_H2_suB, Rnh202_N
DCC	Antibody/Immunoglobulin	yes		Ig_sub2, Ig_sub, FN3_dom
FGFR2	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Ig_sub2
MIR3134	Other/Unknown	no
EBLN1	Other/Unknown	no		P40_nucleoprot_BD-vir, P40_nucleoprot_sub1_BD-vir, P40_nucleoprot_sub2_BD-vir
GATA3	Transcription factor	no		Znf_GATA, Znf_NHR/GATA, TF_GATA-2/3
GATA6	Transcription factor	no		Znf_GATA, GATA_N, Znf_NHR/GATA
GCLC	Enzyme (other)	yes	6.3.2.2	GCS, Gln_synth/guanido_kin_cat_dom
MACROH2A1	Other/Unknown	no		Histone_H2A, Macro_dom, H2A/H2B/H3
H2BC13	Other/Unknown	no		Histone_H2B, H2A/H2B/H3, Histone-fold
LINC03103	Other/Unknown	no
PITX1-AS1	Other/Unknown	no

Expression context

Cohort genes with no expression data: 0.

23 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	2
broad (>20)	30
unknown	0

Top tissues across cohort

Tissue	Cohort genes
adrenal tissue	5
cortical plate	4
right testis	4
primordial germ cell in gonad	3
buccal mucosa cell	3
bronchial epithelial cell	3
male germ line stem cell (sensu Vertebrata) in testis	3
ileal mucosa	3
jejunal mucosa	3
left testis	3
primary visual cortex	2
upper leg skin	2
ganglionic eminence	2
ventricular zone	2
kidney epithelium	2
adrenal cortex	1
right adrenal gland	1
right adrenal gland cortex	1
cardiac muscle of right atrium	1
tendon of biceps brachii	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SYN3	176	broad	marker	primordial germ cell in gonad, cortical plate, primary visual cortex
TBX3	243	ubiquitous	marker	right adrenal gland cortex, right adrenal gland, adrenal cortex
TBX5	129	broad	marker	tendon of biceps brachii, cardiac muscle of right atrium, buccal mucosa cell
HNF1B	74	broad	marker	metanephros cortex, adult mammalian kidney, kidney
TERT	105	broad	yes	stromal cell of endometrium, type B pancreatic cell, olfactory bulb
UGCG	274	ubiquitous	marker	upper leg skin, bronchial epithelial cell, adrenal tissue
BCL11A	247	ubiquitous	marker	cortical plate, ganglionic eminence, primary visual cortex
DLEU1	162	ubiquitous	marker	primordial germ cell in gonad, male germ line stem cell (sensu Vertebrata) in testis, islet of Langerhans
PHIP	302	ubiquitous	marker	bronchial epithelial cell, epithelium of bronchus, ventricular zone
GATA5	106	broad	yes	ileal mucosa, left uterine tube, jejunal mucosa
ELOVL6	255	ubiquitous	marker	right lobe of liver, endothelial cell, esophagus squamous epithelium
BTBD3	298	ubiquitous	marker	cerebellar vermis, adrenal tissue, paraflocculus
SPTLC3	228	ubiquitous	marker	buccal mucosa cell, placenta, skin of abdomen
SORCS1	188	broad	marker	cortical plate, sural nerve, trigeminal ganglion
STARD4	221	ubiquitous	marker	adrenal tissue, ileal mucosa, jejunal mucosa
CIMAP1A	28		yes	left ventricle myocardium, kidney epithelium, epithelial cell of pancreas
DNAJC1	278	ubiquitous	marker	secondary oocyte, pylorus, cardia of stomach
UNC13A	193	broad	marker	right hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex
CLPTM1L	255	ubiquitous	marker	ileal mucosa, kidney epithelium, right lobe of thyroid gland
CTAGE1	13	tissue_specific	yes	right testis, left testis, testis
RNASEH2B	242	ubiquitous	marker	calcaneal tendon, ganglionic eminence, ventricular zone
DCC	154	broad	marker	cortical plate, right testis, left testis
FGFR2	272	broad	marker	C1 segment of cervical spinal cord, spinal cord, corpus callosum
MIR3134	66		yes	adrenal tissue, blood, putamen
EBLN1	7		yes	primordial germ cell in gonad, male germ line stem cell (sensu Vertebrata) in testis, right testis
GATA3	220	broad	marker	upper leg skin, skin of hip, endometrium epithelium
GATA6	204	ubiquitous	marker	germinal epithelium of ovary, parietal pleura, jejunal mucosa
GCLC	291	ubiquitous	marker	bronchial epithelial cell, right uterine tube, olfactory segment of nasal mucosa
MACROH2A1	302	ubiquitous	marker	epithelium of nasopharynx, tongue squamous epithelium, monocyte
H2BC13	130	ubiquitous	yes	bone marrow cell, adrenal tissue, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 5.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
GATA3	5,990
TERT	5,717
PHIP	3,057
MACROH2A1	3,047
H2BC13	2,784
GATA5	2,434
BCL11A	2,389
TBX3	2,379
DNAJC1	2,375
TBX5	2,250

Intra-cohort edges

A	B	Sources
BCL11A	FGFR2	intact
CLPTM1L	TERT	string_interaction
GATA5	TBX5	string_interaction
SPTLC3	UGCG	string_interaction
TBX3	TBX5	string_interaction

Structural data

PDB: 14 · AlphaFold-only: 15 · No structure: 3

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
PHIP	Q8WWQ0	146
FGFR2	P21802	63
TERT	O14746	23
BCL11A	Q9H165	17
MACROH2A1	O75367	13
DCC	P43146	9
TBX5	Q99593	4
RNASEH2B	Q5TBB1	4
HNF1B	P35680	3
GATA3	P23771	3
STARD4	Q96DR4	2
DNAJC1	Q96KC8	2
SYN3	O14994	1
TBX3	O15119	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
GCLC	P48506	93.68
UGCG	Q16739	93.29
ELOVL6	Q9H5J4	92.40
H2BC13	Q99880	87.45
SPTLC3	Q9NUV7	87.25
EBLN1	P0CF75	84.45
BTBD3	Q9Y2F9	83.60
CLPTM1L	Q96KA5	78.54
SORCS1	Q8WY21	77.77
CIMAP1A	Q96PU9	74.04
UNC13A	Q9UPW8	73.58
CTAGE1	Q96RT6	70.45
GATA5	Q9BWX5	59.91
DLEU1	O43261	55.08
GATA6	Q92908	53.48

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 145. Enrichment computed across 32 evidence-associated genes (18 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 18 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Signaling by FGFR2 amplification mutants	1	634.4×	0.057	FGFR2
Signaling by FGFR2 fusions	1	634.4×	0.057	FGFR2
Developmental Lineage of Multipotent Pancreatic Progenitor Cells	2	66.8×	0.057	HNF1B, GATA6
Cardiogenesis	2	47.0×	0.057	TBX5, GATA6
Factors involved in megakaryocyte development and platelet production	3	11.1×	0.067	GATA5, GATA3, GATA6
Defective GCLC causes HAGGSD	1	317.2×	0.076	GCLC
Sphingolipid metabolism	2	18.7×	0.104	UGCG, SPTLC3
DSCAM interactions	1	126.9×	0.107	DCC
Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	1	90.6×	0.107	TERT
Regulation of gene expression in early pancreatic precursor cells	1	79.3×	0.107	HNF1B
Netrin mediated repulsion signals	1	70.5×	0.107	DCC
FGFR2b ligand binding and activation	1	63.4×	0.107	FGFR2
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation	1	63.4×	0.107	GATA6
Caspase activation via Dependence Receptors in the absence of ligand	1	63.4×	0.107	DCC
Role of second messengers in netrin-1 signaling	1	57.7×	0.107	DCC
Glutathione synthesis and recycling	1	52.9×	0.107	GCLC
Regulation of commissural axon pathfinding by SLIT and ROBO	1	52.9×	0.107	DCC
ALK mutants bind TKIs	1	52.9×	0.107	BCL11A
FGFR2c ligand binding and activation	1	48.8×	0.107	FGFR2
Nephron development	1	48.8×	0.107	HNF1B
Pregnenolone biosynthesis	1	45.3×	0.107	STARD4
YAP1- and WWTR1 (TAZ)-stimulated gene expression	1	42.3×	0.107	TBX5
Developmental Lineage of Mammary Stem Cells	1	42.3×	0.107	GATA3
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells	1	39.6×	0.107	HNF1B
DCC mediated attractive signaling	1	39.6×	0.107	DCC
Formation of definitive endoderm	1	39.6×	0.107	GATA6
Activated point mutants of FGFR2	1	37.3×	0.107	FGFR2
Physiological factors	1	37.3×	0.107	TBX5
Serotonin Neurotransmitter Release Cycle	1	35.2×	0.107	SYN3
Phospholipase C-mediated cascade; FGFR2	1	35.2×	0.107	FGFR2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 27 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
hepatoblast differentiation	2	624.1×	6e-04	TBX3, HNF1B
cell fate commitment	4	43.8×	6e-04	GATA5, FGFR2, GATA3, GATA6
atrioventricular bundle cell differentiation	2	416.1×	0.001	TBX3, TBX5
positive regulation of cardiac muscle cell proliferation	3	69.3×	0.001	TBX5, FGFR2, GATA6
cellular response to BMP stimulus	3	62.4×	0.001	GATA5, GATA3, GATA6
in utero embryonic development	5	13.3×	0.003	TBX3, RNASEH2B, FGFR2, GATA3, GATA6
sinoatrial node development	2	156.0×	0.004	TBX5, GATA6
forelimb morphogenesis	2	156.0×	0.004	TBX3, TBX5
negative regulation of dendrite development	2	156.0×	0.004	BCL11A, DCC
negative regulation of transcription by RNA polymerase II	8	5.2×	0.004	TBX3, HNF1B, BCL11A, GATA5, FGFR2, GATA3, GATA6, MACROH2A1
atrioventricular canal development	2	113.5×	0.005	TBX3, GATA6
negative regulation of collateral sprouting	2	113.5×	0.005	BCL11A, DCC
intestinal epithelial cell differentiation	2	113.5×	0.005	GATA5, GATA6
positive regulation of transcription by RNA polymerase II	8	4.4×	0.010	TBX3, TBX5, BCL11A, PHIP, GATA5, FGFR2, GATA3, GATA6
embryonic digestive tract morphogenesis	2	69.3×	0.012	HNF1B, FGFR2
smooth muscle cell differentiation	2	65.7×	0.013	TBX3, GATA6
RNA-templated transcription	1	624.1×	0.013	TERT
type IV hypersensitivity	1	624.1×	0.013	GATA3
ribonucleotide metabolic process	1	624.1×	0.013	RNASEH2B
cholesterol transport involved in cholesterol storage	1	624.1×	0.013	STARD4
DNA strand elongation	1	624.1×	0.013	TERT
negative regulation of transforming growth factor beta2 production	1	624.1×	0.013	GATA6
tube morphogenesis	1	624.1×	0.013	GATA6
regulation of pronephros size	1	624.1×	0.013	HNF1B
fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cell	1	624.1×	0.013	FGFR2
fibroblast growth factor receptor signaling pathway involved in hemopoiesis	1	624.1×	0.013	FGFR2
fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow	1	624.1×	0.013	FGFR2
pronephric nephron tubule development	1	624.1×	0.013	HNF1B
sphingoid biosynthetic process	1	624.1×	0.013	SPTLC3
mesoderm morphogenesis	1	624.1×	0.013	TBX3

Therapeutics

Drugs indicated for this disease

7 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Alfuzosin	Approved (phase 4)
Dutasteride	Approved (phase 4)
Finasteride	Approved (phase 4)
Silodosin	Approved (phase 4)
Tadalafil	Approved (phase 4)
Tamsulosin	Approved (phase 4)
Terazosin	Approved (phase 4)
Cetrorelix	Phase 3 (in late-stage trials)
Doxazosin	Phase 3 (in late-stage trials)
Fexapotide	Phase 3 (in late-stage trials)
Lonidamine	Phase 3 (in late-stage trials)
Saw Palmetto	Phase 3 (in late-stage trials)
Solifenacin	Phase 3 (in late-stage trials)
Topsalysin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Adalimumab, Celecoxib, Degarelix, Epigalocatechin Gallate, Etonogestrel, Lycopene, Onabotulinumtoxina, Ozarelix, Paclitaxel, Sildenafil, Sodium Chloride, Tertomotide, Vardenafil.

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 4 · Undrugged: 28

Druggability breadth: 10 of 32 evidence-associated genes (31%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TERT	BERBERINE
UGCG	MIGLUSTAT
FGFR2	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
FGFR2	59	4
TERT	10	4
UGCG	5	4
GCLC	1	1
SYN3	0	0
TBX3	0	0
TBX5	0	0
HNF1B	0	0
BCL11A	0	0
DLEU1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BERBERINE	4	TERT
DOXORUBICIN	4	TERT
MIGLUSTAT	4	UGCG
ELIGLUSTAT	4	UGCG
PONATINIB	4	FGFR2
PEMIGATINIB	4	FGFR2
NINTEDANIB	4	FGFR2
FEDRATINIB	4	FGFR2
LENVATINIB	4	FGFR2
AXITINIB	4	FGFR2
SORAFENIB	4	FGFR2
INFIGRATINIB PHOSPHATE	4	FGFR2
INFIGRATINIB	4	FGFR2
IBRUTINIB	4	FGFR2
CERITINIB	4	FGFR2
VANDETANIB	4	FGFR2
NINTEDANIB ESYLATE	4	FGFR2
BRIGATINIB	4	FGFR2
ERDAFITINIB	4	FGFR2
FUTIBATINIB	4	FGFR2
PAZOPANIB	4	FGFR2
SUNITINIB	4	FGFR2
DASATINIB	4	FGFR2
ERLOTINIB	4	FGFR2
MIDOSTAURIN	4	FGFR2
RESVERATROL	3	TERT
EPIGALOCATECHIN GALLATE	3	TERT
PERIFOSINE	3	TERT
LUCERASTAT	3	UGCG
VENGLUSTAT	3	UGCG

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 6.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
FGFR2	966	Binding:940, Functional:22, ADMET:4
TERT	391	Binding:389, Functional:2
UGCG	44	Binding:41, Functional:3
PHIP	17	Binding:17
GCLC	14	Binding:14
ELOVL6	10	Binding:10
TBX5	1	Binding:1
SPTLC3	1	Binding:1
CLPTM1L	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
UGCG	2.4.1.80	ceramide glucosyltransferase
ELOVL6	2.3.1.16, 2.3.1.199	acetyl-CoA C-acyltransferase, very-long-chain 3-oxoacyl-CoA synthase
SPTLC3	2.3.1.50	serine C-palmitoyltransferase
RNASEH2B	3.1.26.4	ribonuclease H
FGFR2	2.7.10.1	receptor protein-tyrosine kinase
GCLC	6.3.2.2	glutamate-cysteine ligase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TERT	391
FGFR2	966

Pharmacogenomics

Cohort genes with a PharmGKB record: 30; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
BERBERINE	4	TERT
DOXORUBICIN	4	TERT
MIGLUSTAT	4	UGCG
ELIGLUSTAT	4	UGCG
PONATINIB	4	FGFR2
PEMIGATINIB	4	FGFR2
NINTEDANIB	4	FGFR2
FEDRATINIB	4	FGFR2
LENVATINIB	4	FGFR2
AXITINIB	4	FGFR2
SORAFENIB	4	FGFR2
INFIGRATINIB PHOSPHATE	4	FGFR2
INFIGRATINIB	4	FGFR2
IBRUTINIB	4	FGFR2
CERITINIB	4	FGFR2
VANDETANIB	4	FGFR2
NINTEDANIB ESYLATE	4	FGFR2
BRIGATINIB	4	FGFR2
ERDAFITINIB	4	FGFR2
FUTIBATINIB	4	FGFR2
PAZOPANIB	4	FGFR2
SUNITINIB	4	FGFR2
DASATINIB	4	FGFR2
ERLOTINIB	4	FGFR2
MIDOSTAURIN	4	FGFR2
RESVERATROL	3	TERT
EPIGALOCATECHIN GALLATE	3	TERT
PERIFOSINE	3	TERT
LUCERASTAT	3	UGCG
VENGLUSTAT	3	UGCG

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	TERT, UGCG, FGFR2
B	Phased (≥1) drug, not yet approved	1	GCLC
C	Druggable family + PDB, no drug	2	RNASEH2B, DCC
D	Druggable family + AlphaFold only, no drug	3	ELOVL6, SPTLC3, SORCS1
E	Difficult family or no structure, no drug	23	SYN3, TBX3, TBX5, HNF1B, BCL11A, DLEU1, PHIP, GATA5, BTBD3, STARD4 (+13 more)

Undrugged target profiles

28 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
CLPTM1L	1	TERT
SYN3	0	—
TBX3	0	—
TBX5	1	—
HNF1B	0	—
BCL11A	0	—
DLEU1	0	—
PHIP	17	—
GATA5	0	—
ELOVL6	10	—
BTBD3	0	—
SPTLC3	1	—
SORCS1	0	—
STARD4	0	—
CIMAP1A	0	—
DNAJC1	0	—
UNC13A	0	—
CTAGE1	0	—
RNASEH2B	0	—
DCC	0	—
MIR3134	0	—
EBLN1	0	—
GATA3	0	—
GATA6	0	—
MACROH2A1	0	—
H2BC13	0	—
LINC03103	0	—
PITX1-AS1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 549.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	333
PHASE4	65
PHASE3	61
PHASE2	42
PHASE1	26
PHASE1/PHASE2	10
PHASE2/PHASE3	7
EARLY_PHASE1	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06710327	PHASE4	NOT_YET_RECRUITING	Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation
NCT07204002	PHASE4	NOT_YET_RECRUITING	Comparison of Convective Water Vapor Ablation (Convective Water Vapor Energy, WAVE™) With the Rezum™ System Versus Holmium Laser Enucleation of the Prostate (HoLEP) Versus Bipolar Transurethral Resection of the Prostate (TUR-P) in Patients With Benign Prostatic Syndrome (BPS) - A Randomized Study
NCT07357324	PHASE4	RECRUITING	A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate
NCT07460518	PHASE4	NOT_YET_RECRUITING	Tranexamic Acid for Bleeding Reduction During TURP Surgery
NCT07467343	PHASE4	NOT_YET_RECRUITING	Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial
NCT00130767	PHASE4	UNKNOWN	Kinetics of the Finasteride Prostate Induced Apoptosis
NCT00194675	PHASE4	COMPLETED	TRADE-Testosterone Replacement and Dutasteride Effectiveness
NCT00199550	PHASE4	COMPLETED	Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)
NCT00364585	PHASE4	COMPLETED	A Prospective Evaluation of the GreenLight Model 120 Laser
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00379067	PHASE4	COMPLETED	A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
NCT00421421	PHASE4	TERMINATED	Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter
NCT00465101	PHASE4	COMPLETED	A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization
NCT00542165	PHASE4	COMPLETED	Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy
NCT00637715	PHASE4	COMPLETED	Once Daily Given Alfuzosin in the Treatment of BPH
NCT00687388	PHASE4	WITHDRAWN	The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia
NCT00690950	PHASE4	UNKNOWN	A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart
NCT00696761	PHASE4	COMPLETED	The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
NCT00701779	PHASE4	COMPLETED	Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
NCT00771394	PHASE4	COMPLETED	Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
NCT00827814	PHASE4	COMPLETED	Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction
NCT00836823	PHASE4	COMPLETED	Evaluation of Symptom-specific Goal Achievement
NCT00880672	PHASE4	COMPLETED	Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate
NCT00922506	PHASE4	COMPLETED	Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)
NCT00939120	PHASE4	COMPLETED	Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
NCT01259531	PHASE4	COMPLETED	Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
NCT01260129	PHASE4	COMPLETED	Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
NCT01301599	PHASE4	COMPLETED	Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)
NCT01494337	PHASE4	COMPLETED	Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP)
NCT01500057	PHASE4	COMPLETED	Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
NCT01604811	PHASE4	COMPLETED	Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
NCT01631149	PHASE4	COMPLETED	Effect of Deep BLock on Intraoperative Surgical Conditions
NCT01675895	PHASE4	COMPLETED	Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration
NCT01736033	PHASE4	UNKNOWN	Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients
NCT01747577	PHASE4	COMPLETED	Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
NCT01757769	PHASE4	COMPLETED	Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
NCT01861041	PHASE4	UNKNOWN	Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy.
NCT02006303	PHASE4	UNKNOWN	Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients
NCT02021032	PHASE4	UNKNOWN	Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)
NCT02072499	PHASE4	COMPLETED	KTP Green Light Prostatectomy Compared With Open Prostatectomy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TAMSULOSIN	4	95
ALFUZOSIN	4	30
SOLIFENACIN	4	27
DUTASTERIDE	4	20
TADALAFIL	4	16
SILODOSIN	4	13
FINASTERIDE	4	10
CETRORELIX	4	4
CEPHALEXIN ANHYDROUS	4	3
DOXAZOSIN	4	3
MIRABEGRON	4	3
TALAPORFIN SODIUM	4	3
CIPROFLOXACIN	4	2
ALCOHOL	4	1
BUPIVACAINE	4	1
CELECOXIB	4	1
DEGARELIX	4	1
DICLOFENAC SODIUM	4	1
ETONOGESTREL	4	1
FUROSEMIDE	4	1
METHOXYFLURANE	4	1
NITROFURANTOIN	4	1
OXYGEN	4	1
PACLITAXEL	4	1
PYRIDOSTIGMINE	4	1
RALOXIFENE	4	1
FEXAPOTIDE	3	10
TOPSALYSIN	3	3
LONIDAMINE	3	2
OZARELIX	3	2